XML 48 R20.htm IDEA: XBRL DOCUMENT v3.19.2
Stockholders' Equity
9 Months Ended
Jul. 31, 2019
Equity [Abstract]  
Stockholders' Equity

NOTE 13 - STOCKHOLDERS’ EQUITY:

 

  a. Treasury Stock. The Company utilizes the cost method of accounting for treasury stock. The cost of reissued shares is determined under the last-in, first-out method. The Company did not purchase any shares during the nine and three months ended July 31, 2019. The Company purchased 236,586 shares for $1,129,050 during the year ended October 31, 2018.
     
  b. Share Repurchase Program. On September 10, 2017, the Company announced that the Board of Directors had approved a share repurchase program (the “2017 Share Repurchase Program”) pursuant to which the Company may repurchase up to $2 million of the outstanding common stock from time to time on the open market and in privately negotiated transactions subject to market conditions, share price and other factors. The timing and amount of any shares repurchased will be determined based on the Company’s evaluation of market conditions and other factors. The 2017 Share Repurchase Program may be discontinued or suspended at any time. Pursuant to the terms of the 2017 Share Repurchase Program, the Company purchased 236,586 shares for $1,129,050 during the year ended October 31, 2018. As of October 31, 2018, the 2017 Share Repurchase Program has been discontinued.
     
    Stock Options. The Company has an incentive stock plan, the 2013 Equity Compensation Plan (the “2013 Plan”), and on April 19, 2019, has granted stock options to employees, officers and non-employee directors from the 2013 Plan. Options granted under the 2013 Plan may be Incentive Stock Options or Nonqualified Stock Options, as determined by the Administrator at the time of grant. As of July 31, 2019, the Board of Directors approved 1,000,000 options.
     
   

During the nine months ended July 31, 2019, the Company granted stock option awards to five board members to purchase an aggregate 59,000 shares of the Company’s common stock at $5.43 per share.

 

The stock options have an expected term of six years and will vest over a twelve month service period.

 

The stock options have an aggregate grant date fair value of approximately $233,050. The Company also granted stock option awards to certain officers and employees to purchase an aggregate of 941,000 shares of the Company’s common stock at an exercise price of $5.43 per share. The stock options have an expected term of six years and will vest over a three year service period. These stock options have an aggregate grant date fair value of approximately $2,277,220.

 

The following table represents stock option activity for the nine months ended July 31, 2019:

 

   Stock Options   Exercise Price   Contractual Life   Aggregate Intrinsic 
   Outstanding   Exercisable   Outstanding   Exercisable   (Years)   Value 
Balance October 31, 2018   -          -    -         -    -         - 
Granted   1,000,000        $5.43    -    10    - 
Exercised   -    -    -    -    -    - 
Cancelled   -    -    -    -    -    - 
Balance July 31, 2019   1,000,000    -   $5.43    -    10    - 

 

The Company recorded $203,868 and $228,868 of stock-based compensation in the three and nine months ended July 31, 2019, respectively.

 

The outstanding stock compensation expense as of July 31, 2019 was approximately $2,281,402.